What is Lewy Body Dementia? The patient will have symptoms such as stiff body, shaking hands and unstable walking.
What is Lewy Body Dementia? In fact, this is a fairly common neurodegenerative disease, but people are unfamiliar with it. The prevalence of this disease ranks second among all dementias, second only to Alzheimer's disease. Mainly because of the abnormal protein deposition in the brain tissue of patients, called Lewy bodies. These abnormal protein accumulations, like garbage in the brain, will eventually poison the nerves, which will not only lead to the deterioration of patients' cognitive functions (learning, memory, recognition, language, intelligence, etc.). ), but also lead to dementia. With the deterioration of the disease, patients gradually appear stiff limbs, shaking hands, unstable walking, repeated falls and other phenomena, and often have hallucinations or other mental symptoms, such as delusion or depression. The above symptoms are similar to those of Alzheimer's disease or Parkinson's disease, so it is not easy to make a differential diagnosis at the initial stage.
Robin williams's widow Susan once told the media that Robin's symptoms before his death included stiffness, unsteady gait and confusion. A few months before his death, his condition deteriorated and he became stubborn and could not judge the distance correctly. Once, Susan found that his muscles were completely stiff and his head was bleeding profusely because he hit the door. Susan said, "We had a nightmare." Robin knew that he was losing his mental abilities. He tried to be normal, but he failed in the last 1 month.
Dementia tsunami! 204 1 There may be as many as 670,000 people.
Professor Lai Deren, chairman of Taiwan Province Dementia Association, pointed out that the total population of dementia in Taiwan Province Province has exceeded 260,000 in 20 16, and it is estimated that by 20041year, there may be as many as 670,000 people, that is, on average, 3 people will suffer from dementia every 100 people. According to the International Dementia Association, the global total economic cost caused by dementia exceeds $800 billion every year. In Taiwan Province Province, the annual care cost for each dementia patient is nearly NT$ 6,543,800,000, which has caused a great burden to the patient's family, society and country. Therefore, it is urgent to develop better therapeutic drugs.
1976 Japanese scholar Kosaka and his colleagues first published a case anatomy report of a dementia patient, in which many abnormal proteins (Lewy bodies; Lewy corpuscles), patients not only have progressive dementia, but also have motor dysfunction. At that time, it was considered as a rare variant dementia, and it was not until 1980 that the disease gradually attracted attention. In the general elderly population, the prevalence rate of Lewy dementia is 0.1~ 5%; It is 1.7~30.5% in all dementia people. The ratio of male to female with Lewy body dementia is 1.5: 1. The onset usually begins after the age of 50, with an average onset age of 75. With the gradual increase of age, the prevalence rate is higher, and the average survival time after illness is about 5~7 years.
Amyloid β-protein and α -synuclein will appear in the brain of dementia patients with Lewy bodies, and these two proteins will interact with each other, leading to degeneration and accumulation of α -synuclein, resulting in greater toxicity. Similarly, amyloid will also appear in the brain tissue of patients with Alzheimer's disease; However, α -synuclein appears in the brains of patients with Parkinson's disease, so Lewy body dementia has both pathological and symptomatic features of Alzheimer's disease and Parkinson's disease. Professor He Yingrui pointed out that "Ceftriaxone" can not only regulate the gene to inhibit the production of amyloid, but also combine with α -synuclein to prevent protein's degeneration, which can be said to be a pathological elimination of toxins in patients' brains.
What is Ceftriaxone? It is an ancient antibiotic, mainly used to treat meningitis, pneumonia and gonorrhea.
Ceftriaxone is an ancient antibiotic, which is mainly used to treat gram-positive and gram-negative bacterial infections (such as meningitis, pneumonia and gonorrhea).
There is also an important substance ── glutamate, which will lead to nerve degeneration. Under normal circumstances, glutamic acid is a neurotransmitter, which is responsible for maintaining normal nerve function. However, when excessive glutamate appears in brain tissue, it will poison nerves. At present, it is known that almost all neurodegenerative diseases are related to glutamate excess. Professor He Yingrui confirmed that "Ceftriaxone" can begin to eliminate glutamic acid and reduce brain cell death and neuroinflammation. What is more exciting is that ceftriaxone can also promote neurogenesis and grow new cells. Therefore, ceftriaxone can not only remove brain toxins and slow down neurodegeneration, but also repair damaged brain tissue and treat neurodegenerative diseases.
Lewy body dementia, Alzheimer's disease and Parkinson's disease are treated with different drugs.
Dr. Qiu Baiyi, director of the Department of Neurology, Xiuchuan Hospital, Changhua, pointed out that although Lewy body dementia, Alzheimer's disease and Parkinson's disease have similar symptoms and pathological features, there are great differences in the treatment drugs and patients' responses to drugs for these three diseases, so correct diagnosis is necessary for correct treatment.
Professor He's research team has just obtained the approval of FDA and the United States, and is conducting a clinical trial of a new drug (multi-country, multi-center phase II trial). It is expected that the recently patented medical technology for the treatment of dementia with Lewy bodies will enter clinical trials as soon as possible, bringing better treatment options for patients.
The research team of Professor He Yingrui from the Department of Psychology, Sun Yat-sen University of Medical Sciences confirmed that "Ceftriaxone" can treat dementia with Lewy bodies, and recently applied for patents in Taiwan Province Province, China, Japan and Canada. Amyloid β-protein and α -synuclein will appear in the brain of dementia patients with Lewy bodies, and these two proteins will interact with each other, leading to degeneration and accumulation of α -synuclein, resulting in greater toxicity.